TVTX
Travere Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$62.76
−3.06%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$64.89
From 52W high−7.05%
Volume2.23M
Market cap$5.92B
P/E (TTM)—
P/S (TTM)10.0x
Div yield—
Key dataSep 18, 2026
Open
$64.89
From 52W high
−7.05%
Volume
2.23M
Market cap
$5.92B
ValuationView details →
P/E (Fwd)
32.0x
EV/EBITDA
3914.2x
P/E (TTM)
—
RSI (14)
45.5
MomentumView details →
1D Return
−3.06%
YTD Return
+64.07%
SummaryUpdated Jun 1, 2026
Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company founded in 2008 and headquartered in San Diego, California. Originally incorporated as Retrophin, Inc., the company rebranded to Travere Therapeutics in November 2020. The company specializes in developing and commercializing therapies for rare diseases, with a particular focus on rare kidney disorders and metabolic conditions. Travere has successfully transitioned from a development-stage company to a commercial-stage biopharmaceutical enterprise, with multiple approved products generating revenue and a robust pipeline of investigational therapies targeting significant unmet medical needs in rare disease populations.
Similar companies
Latest newsMore news →
Travere Therapeutics reported that the launch of FILSPARI for focal segmental glomerulosclerosis (FSGS) exceeded expectations, and the company is expanding its renal pipeline.33d agoTravere Therapeutics reported a second-quarter loss of $0.37 per share, missing the Zacks Consensus Estimate of a loss of $0.14, and compared to a loss of $0.14 per share a year ago.47d ago